mtPIrtv in Andalusian 2-2-2016

mtPIrtv in Andalusian 2-2-201

Baseline patients’ characteristics.

<p>Baseline patients’ characteristics.</p

Kaplan-Meier estimations of the efficacy as determined by on-treatment analysis applying different criteria for virological failure.

<p>Kaplan-Meier estimations of the efficacy as determined by on-treatment analysis applying different criteria for virological failure.</p

Percentages of detectable HIV-RNA determinations (red) according to virological behavior during the follow-up for ritonavir-boosted protease inhibitor monotherapy.

<p>Undetectable viremia (green).</p

Efficaccy rates.

<p>A) Efficacy rates according to the ritonavir-boosted protease inhibitor used by intention-to-treat and by on-treatment analyses. B) Virological efficacy rates according to virological failure (VF) defined as >200 copies/mL or C) >50 copies/mL or treatment change due to a single positive viremia, according to the presence or absence of previous VF on a non-boosted protease inhibitor- and/or ritonavir-boosted protease inhibitor-based regimen (PI/rtv). DRV/rtv, darunavir/ritonavir; LPV/rtv, lopinavir/ritonavir.</p

Proportion of patients with increased aminotransferases levels at any time-point throughout the follow-up.

<p>Proportion of patients with increased aminotransferases levels at any time-point throughout the follow-up.</p

Change in lipid plasma levels (mg/dL) throughout the follow-up.

<p>A: patients with normal baseline values. B: patients with abnormal baseline values on previous NNRTIs- or PI/rtv-based regimens. CT: total cholesterol. HDL-C: high-density lipoprotein cholesterol. LDL-C: low-density lipoprotein cholesterol. TG: triglycerides.</p

Genotypic resistance tests at virological failure.

<p>RT, reverse transcriptase. wt: wild-type. VL, viral load. VF, virogical failure.</p><p>*Mutation scoring according to reference 22.</p

CONSORT flow diagram showing disposition of patients throughout the study from baseline to week 24.

<p>CONSORT flow diagram showing disposition of patients throughout the study from baseline to week 24.</p

Comparison of adherence and virological failure between arms.

<p>Comparison of adherence and virological failure between arms.</p